Evangelos Fousteris

Dr. Evangelos Fousteris

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in International Journal of Cardiology
Verified
Journal Article
Closed access
Evangelos FousterisEvangelos Fousteris
Evangelos Fousteris
ATAnastasios Theodosis-Georgilas
Anastasios Theodosis-Georgilas
SCStelios Chantanis
Stelios Chantanis
PSPanayota Spiropoulou
Panayota Spiropoulou
Sophie I. MavrogeniSophie I. Mavrogeni
Sophie I. Mavrogeni
AMAndreas Melidonis
Andreas Melidonis

16 September 2013 in BMC Neurology
Verified
Journal Article
Open access
PDF file
VDVasileios Dragoumanos
Vasileios Dragoumanos
KTKonstantinos N Tzirogiannis
Konstantinos N Tzirogiannis
GPGeorgios Panoutsopoulos
Georgios Panoutsopoulos
KKKonstantinos Krikonis
Konstantinos Krikonis
Evangelos FousterisEvangelos Fousteris
Evangelos Fousteris
AMAndreas Melidonis
Andreas Melidonis
Background: Diabetes constitutes a risk factor for stroke that also aggravates stroke prognosis. Several prognostic models have been developed for the evaluation of neurologic status, severity, short-term functional outcome and mortality of stroke patients. IScore is a novel tool recently developed in order to predict mortality rates within 30 days and 1 year after ischemic stroke and diabetes is not included in the scoring scale of IScore. The aim of the present study was to evaluate and compare IScore validity in ischemic stroke patients with and without diabetes. Methods: This prospective study included 312 consecutive Caucasian patients with type 2 diabetes and 222 Caucasian patients without diabetes admitted for ischemic stroke in a tertiary Greek hospital. Thirty-day and 1-year IScores were individually calculated for each patient and actual mortality was monitored at the same time intervals. IScore’s predictive ability and calibration was evaluated and compared for ischemic stroke patients with and without diabetes. The performance of IScore for predicting 30 and 1-year mortality between patients with and without diabetes was assessed by determining the calibration and discrimination of the score. The area under the receiver operating characteristic curve was used to evaluate the discriminative ability of IScore for patients with and without diabetes, whereas the calibration of IScore was assessed by the Hosmer–Lemeshow goodness-of fit statistic. Results: Baseline population characteristics and mortality rates did not differ significantly for both cohorts. IScore values were significantly higher for patients with diabetes at 30 days and 1 year after ischemic stroke and patients with diabetes presented more frequently with lacunar strokes. Based on ROC curves analysis IScore’s predictive ability for 30 day mortality was excellent, without statistically significant difference, for both cohorts. Predictive ability for 1 year mortality was also excellent for both groups with significantly better ability for patients with diabetes especially at high score values. Calibration of the model was good for both groups of patients. Conclusions: IScore accurately predicts mortality in acute ischemic stroke Caucasian patients with and without diabetes with higher efficacy in predicting 1 year mortality in patients with diabetes especially with high scores.

23 July 2025 in Biomedicines
Verified
Journal Article
Open access
TKTheocharis Koufakis
Theocharis Koufakis
DKDimitrios Kouroupis
Dimitrios Kouroupis
GDGeorgios Dimakopoulos
Georgios Dimakopoulos
TGTheofylaktos Georgiadis
Theofylaktos Georgiadis
Areti KourtiAreti Kourti
Areti Kourti
Kali MakedouKali Makedou
Kali Makedou
Background/Objectives: The role of intestinal dysbiosis as an important driver of inflammation in metabolic disorders is becoming increasingly evident. Beta-defensin 2 is an antimicrobial peptide that contributes to innate immunity, while recently it has been suggested as a novel biomarker of gut dysbiosis. However, its role in obesity remains unexplored. This study aimed to compare circulating beta-defensin 2 levels between individuals with overweight and obesity and lean controls. An additional objective was to explore potential correlations between beta-defensin 2 and other inflammatory markers in this population. Methods: The study population consisted of 81 participants (61.7% females) divided into obesity (n = 27), overweight (n = 34), and normal body mass index (n = 20) groups. All participants were free of infection and diabetes mellitus. Beta-defensin 2, interleukin-6, presepsin, high-sensitivity C-reactive protein (hs-CRP), and ferritin were evaluated in the study groups. Results: We did not find significant differences in beta-defensin 2 levels between the groups (p = 0.936). In contrast, hs-CRP levels were higher in people with obesity compared to the sum of participants in the overweight and control groups (p = 0.044), after adjusting for the effects of age, sex, smoking, and vitamin D status. Furthermore, a positive correlation was established between beta-defensin 2 and presepsin values (p = 0.012). Conclusions: The results of the present study demonstrate that obesity is characterized by an aggravation of inflammation, as expressed by elevated hs-CRP levels. Although the study design cannot prove causal relationships, our findings also suggest that beta-defensin 2 levels correlate with the magnitude of systemic inflammation in infection-free individuals living with obesity. The value of the combined evaluation of different biomarkers in obesity-related outcomes warrants further investigation by larger studies.

21 February 2026 in Current Obesity Reports
Verified
Journal Article
Open access
PDF file
ATAnastasios Tentolouris
Anastasios Tentolouris
TKTheocharis Koufakis
Theocharis Koufakis
Evangelos FousterisEvangelos Fousteris
Evangelos Fousteris
Purpose of Review: Overweight and obesity are increasingly common in people with type 1 diabetes mellitus (T1DM). This narrative review synthesizes current evidence on the epidemiology and mechanisms linking excess adiposity with T1DM, the obesity-associated burden of complications, and approaches to obesity management in this population. Recent Findings: Excess adiposity is now frequent in people with T1DM, approaching general-population prevalence, and obesity may also increase the risk of incident T1DM. In T1DM, weight gain reflects intersecting drivers, including intensive insulin therapy, hypoglycemia-related compensatory intake and activity avoidance, obesity-related insulin resistance, and overlapping genetic/hormonal determinants. Across multiple cohorts, higher adiposity is associated with poorer glycemic control and increased risk of cardiovascular events and mortality, as well as higher risks of retinopathy, diabetic kidney disease, and neuropathy. Evidence to guide treatment in T1DM remains limited. Lifestyle approaches require individualization to minimize hypoglycemia and ketosis. RCTs of adjunct liraglutide demonstrate weight loss and insulin-sparing effects but signal dose-dependent risks of hypoglycemia and ketosis. Early RCTs with semaglutide and tirzepatide suggest substantial weight loss and improved glycemic metrics in selected settings, with vigilance for ketosis. Sodium-glucose cotransporter-2 inhibitors have shown modest HbA1c reductions with small but clinically meaningful weight loss in T1DM; however, they are associated with an increased risk of diabetic ketoacidosis. Bariatric surgery yields large weight loss but only modest glycemic benefit and carries risk of metabolic instability. Summary: Obesity is a common, clinically important comorbidity in T1DM, linked to poorer glycemic outcomes and complications. Longer-term, T1DM-specific RCTs are needed to guide weight management and define the benefit-risk of emerging therapies.

1 November 2016 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
Evangelos FousterisEvangelos Fousteris
Evangelos Fousteris
APAthanasia Papazafiropoulou
Athanasia Papazafiropoulou
CTChristos Tountas
Christos Tountas
Angeliki M. AngelidiAngeliki M. Angelidi
Angeliki M. Angelidi
SMSpiridon Matsagos
Spiridon Matsagos
AMAndreas Melidonis
Andreas Melidonis

15 May 2026 in Nutrition
Verified
Journal Article
Closed access
NANicholaos George Angelopoulos
Nicholaos George Angelopoulos
ARAndreas Rizoulis
Andreas Rizoulis
ABAnastasios Boniakos
Anastasios Boniakos
Evangelos FousterisEvangelos Fousteris
Evangelos Fousteris
VMVoula Mentzelopoulou
Voula Mentzelopoulou
RPRodis D. Paparodis
Rodis D. Paparodis